Prolonged Hypogammaglobulinemia in a Child With Down Syndrome After Treatment of Acute Lymphoblastic Leukemia With Immunochemotherapy Including Blinatumomab
- 21 February 2025
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31626
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenNew England Journal of Medicine, 2025
- The immune system in Down Syndrome: Autoimmunity and severe infectionsImmunological Reviews, 2023
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Inborn Errors of Adaptive Immunity in Down SyndromeJournal of Clinical Immunology, 2020
- Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in ChildrenNew England Journal of Medicine, 2020
- Immune Dysfunction After Completion of Childhood Leukemia TherapyJournal of Pediatric Hematology/Oncology, 2017
- Intrinsic defect of the immune system in children with Down syndrome: a reviewClinical and Experimental Immunology, 2009
- FCGR3A‐158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non‐Hodgkin’s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantationEuropean Journal of Haematology, 2009
- Risks of leukaemia and solid tumours in individuals with Down's syndromeThe Lancet, 2000